Back to Interventions
Substance / Medication

Colestipol

SNOMED 372811005UMLS C0009279

Overview

Active Ingredient
colestipol
RxNorm CUI
2685

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Hyperlipoproteinemia
Hypercholesterolemia
Hypertriglyceridaemia
Disorder of coronary artery

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

1 trials linked to this intervention

1
Total Trials
0
Recruiting
1
With Results

Recent Trials

A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction

NCT00203476Phase 4Completed30 enrolled
View all 1 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:
Colesevelam and colestipol: novel medication resins in the gastrointestinal tract.
Arnold Michael A, Swanson Benjamin J, Crowder Clinton D et al. · Am J Surg Pathol · 2014
PMID: 24921636Observational
Colestipol granules in the colon: macroscopic and microscopic findings.
Gonzalez Raul S, Schwartz David A, Shi Chanjuan · Histopathology · 2015
PMID: 25406854Case Report
Colestipol-induced hepatotoxicity.
Sirmans S M, Beck J K, Banh H L et al. · Pharmacotherapy · 2001
PMID: 11310528Case Report
Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholeserolemia heterozygotes. 1983.
Bilheimer David W, Grundy Scott M, Brown Michael S et al. · Atheroscler Suppl · 2004
PMID: 15531277Other
Tolerability and efficacy of colestipol hydrochloride for accelerated elimination of teriflunomide.
Robertson Derrick, Dixon Crystal, Aungst Angela et al. · Expert Rev Clin Pharmacol · 2017
PMID: 29064296Trial
Feasibility study of colestipol as an oral phosphate binder in hemodialysis patients.
Hood Christopher J, Wolley Martin J, Kam Angela L et al. · Nephrology (Carlton) · 2015
PMID: 25557531Trial
Treatment of erythropoietic protoporphyria with the oral sorbent colestipol: a proof-of-concept clinical trial.
Tishler Peter V, Rosner Bernard · J Am Acad Dermatol · 2014
PMID: 24438965Trial
Alteration of aluminium inhibition of synaptosomal (Na(+)/K(+))ATPase by colestipol administration.
Silva V S, Oliveira L, Gonçalves P P · J Inorg Biochem · 2013
PMID: 23829947Preclinical
Effect of concomitant colestipol hydrochloride administration on the bioavailability of diltiazem from immediate- and sustained-release formulations.
Turner Scott W, Jungbluth Gail L, Knuth Dean W · Biopharm Drug Dispos · 2002
PMID: 12469330Trial
Sorption of fluoroacetate (compound 1080) by Colestipol, activated charcoal and anion-exchange in resins in vitro and gastrointestinal decontamination in rats.
Norris W R, Temple W A, Eason C T et al. · Vet Hum Toxicol · 2000
PMID: 11003116Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Colestipol (substance)
SNOMED CT
372811005
UMLS CUI
C0009279
RxNorm CUI
2685

Clinical Data

This intervention maps to 4 entities in the Healos knowledge graph.

4
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
1
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.